Table 2.
Patient Characteristics
| Patient Characteristics | Total, n = 990 |
|---|---|
| Age | |
| Mean ± SD | 48.8 ± 10.6 y |
| Range | 23–77 y |
| Menopausal Status | |
| Premenopause | 464 (47) |
| Perimenopause | 33 (3) |
| Postmenopause | 291 (29) |
| Not available | 202 (20) |
| Race | |
| White | 784 (79) |
| African American | 121 (12) |
| Asian | 68 (7) |
| Native Hawaiian or Pacific Islander | 5 (1) |
| American Indian or Alaska Native | 4 (0.4) |
| Mixed Race | 7 (1) |
| Not Available | 1 (0.1) |
| Molecular Subtype | |
| HR+, HER2− | 380 (38) |
| HR+, HER2+ | 156 (16) |
| HR−, HER2+ | 89 (9) |
| HR−, HER2− | 363 (37) |
| Not available | 2 (0.2) |
| Assigned Chemotherapy | |
| Standard Neoadjuvant Chemotherapy | 211 (21) |
| Experimental Drug Arms | 777 (78) |
| Not Available | 2 (0.2) |
| Treatment Response | |
| pCR | 324 (33) |
| Non-pCR | 666 (67) |
Unless otherwise specified, data represent the number of patients and data in parentheses are percentages.
Abbreviations: SD, standard deviation; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete response.